Insider Buying: Tempest Therapeutics, Inc. (NASDAQ:TPST) CEO Purchases 35,000 Shares of Stock

Tempest Therapeutics, Inc. (NASDAQ:TPSTGet Free Report) CEO Stephen R. Brady bought 35,000 shares of the stock in a transaction on Wednesday, July 3rd. The shares were acquired at an average cost of $2.11 per share, for a total transaction of $73,850.00. Following the completion of the transaction, the chief executive officer now directly owns 46,376 shares of the company’s stock, valued at $97,853.36. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Tempest Therapeutics Stock Performance

Tempest Therapeutics stock opened at $2.15 on Thursday. Tempest Therapeutics, Inc. has a 12 month low of $0.17 and a 12 month high of $9.77. The stock has a market cap of $47.77 million, a price-to-earnings ratio of -1.25 and a beta of -1.73. The business has a 50 day moving average price of $2.92 and a two-hundred day moving average price of $3.55. The company has a quick ratio of 3.13, a current ratio of 3.13 and a debt-to-equity ratio of 0.20.

Tempest Therapeutics (NASDAQ:TPSTGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.08. As a group, equities analysts forecast that Tempest Therapeutics, Inc. will post -1.57 EPS for the current year.

Hedge Funds Weigh In On Tempest Therapeutics

An institutional investor recently bought a new position in Tempest Therapeutics stock. MayTech Global Investments LLC bought a new stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPSTFree Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $44,000. Tempest Therapeutics accounts for approximately 0.0% of MayTech Global Investments LLC’s investment portfolio, making the stock its 29th largest holding. MayTech Global Investments LLC owned 0.05% of Tempest Therapeutics as of its most recent filing with the SEC. 22.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently issued reports on TPST. Scotiabank initiated coverage on shares of Tempest Therapeutics in a research note on Thursday, March 14th. They issued a “sector outperform” rating and a $13.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $47.00 price target on shares of Tempest Therapeutics in a research report on Thursday, June 20th. William Blair reissued an “outperform” rating on shares of Tempest Therapeutics in a research report on Wednesday, March 20th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $8.00 target price on shares of Tempest Therapeutics in a report on Friday, June 21st. Five investment analysts have rated the stock with a buy rating, According to data from, the stock has a consensus rating of “Buy” and an average price target of $20.75.

Check Out Our Latest Analysis on Tempest Therapeutics

Tempest Therapeutics Company Profile

(Get Free Report)

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.

Recommended Stories

Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with's FREE daily email newsletter.